About Axsome Therapeutics Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.axsome.com/
Frequently Asked Questions
What is the 52-week range for AXSM?
The 52-week high is $260.19 and the 52-week low is $117.3.
What is the P/E ratio for AXSM?
The P/E ratio data is currently unavailable.
What is the dividend yield for AXSM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -255.60%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -24.68%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 71.94.
Analyst Recommendation Trends
Wall Street analyst consensus for AXSM over the last few months:
Latest AXSM News
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.
Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.
Deutsche Bank Maintains Buy on Axsome Therapeutics, Lowers Price Target to $267
Deutsche Bank analyst David Hoang maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $280 to $267.
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $247
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $251 to $247.
$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today
Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 24.39% on an annualized basis producing an average annual return of 37.87%. Currently, Axsome Therapeutics has a market
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Truist Securities Maintains Buy on Axsome Therapeutics, Raises Price Target to $285
Truist Securities analyst Srikripa Devarakonda maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the price target from $200 to $285.
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that agitation negatively impacted their loved one’s quality of life, and three in four wish they had recognized symptoms sooner Results from the survey were recently presented at Psych Congress 2026 in New Orleans, Louisiana Survey conducted by The Harris Poll and in collaboration wi
Axsome Therapeutics Highlights Alzheimer’s Agitation Impact In Shared Goals Survey
The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disruptedNinety-seven percent of care partners reported that
5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In
U.S. stocks ended mixed; the Dow had its worst week since March. Benzinga highlights top picks from five accurate analysts, including ON, AXSM and LLY.
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer’s disease agitation, while management expects operating expenses to remain relatively stable in the
Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues
Axsome Therapeutics has turned into a much bigger story on the market over the past few years, and the question now is whether the current share price can be squared with the sales that support it. For investors watching the recent swings, the key issue is how much revenue power is already baked into today’s valuation. Over the past 5 years the stock has delivered a very large total return of about 7x, which puts a lot of focus on whether that move is backed by the company’s underlying sales...
Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story?
Earlier this week, Axsome Therapeutics highlighted new clinical data in major depressive disorder and Alzheimer’s disease agitation at Psych Congress 2026 in New Orleans, including outcomes for its dextromethorphan-bupropion therapy. By showcasing fresh and encore data across its psychiatry and neurology portfolio, Axsome put the breadth of its central nervous system pipeline in front of a clinically focused audience that can influence real-world adoption. We’ll now examine how this new...
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
Axsome Therapeutics (NASDAQ:AXSM) executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference. Chief Operating Officer Mark Jacobson said the company has three ma
Axsome Therapeutics (AXSM) Reported New Clinical Data In Depression And Alzheimer’s Agitation
Axsome Therapeutics (NasdaqGM:AXSM) reported new clinical data in major depressive disorder and Alzheimer’s disease agitation at a leading psychiatry congress. The presentations focused on key programs in Axsome’s central nervous system pipeline aimed at treating mood and neuropsychiatric symptoms. Management highlighted how the new findings may inform future study designs and regulatory interactions for these indications. These fresh data in depression and Alzheimer’s agitation only capture...
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?
Or are its best days in the rearview mirror?
Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a platform that proved itself at global scale and keeps finding new diseases to target.
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Axsome is generating revenue from approved drugs but missing estimates and widening losses. Revolution Medicines just changed the standard of care for one of the deadliest cancers in existence.
Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target
Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.
Is Axsome Therapeutics a Buy on the Dip?
The stock slipped about 15% over the past three months.
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer’s disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana. Details of the data presentations
Axsome Therapeutics, Inc. (AXSM) Presents at H.C. Wainwright 28th Annual Global Investment Conference Prepared Remarks Transcript
Axsome Therapeutics, Inc. (AXSM) H.C.
Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 1:50 PM EDTCompany ParticipantsMark Jacobson -...
AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’
Citing Bloomberg Symphony figures for the 30-milligram starter dose used when doctors begin treatment, a Mizuho analyst said new prescriptions for Auvelity rose 32% from July to August.
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 2:45 PM EDTCompany ParticipantsMark Jacobson...
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.
Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 3:45 PM EDTCompany ParticipantsMark Jacobson - Chief...
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-03 | Jacobson Mark L. | -10,000 | - | - |
| 2026-09-03 | Jacobson Mark L. | -10,000 | $208.65 | $2,086,500 |
| 2026-09-03 | Jacobson Mark L. | +10,000 | $12.95 | $129,500 |
| 2026-08-06 | TABUTEAU HERRIOT | -4,660 | - | - |
| 2026-08-06 | TABUTEAU HERRIOT | -4,660 | $213.95 | $997,007 |
| 2026-08-06 | TABUTEAU HERRIOT | +4,660 | $4.95 | $23,067 |
| 2026-08-05 | TABUTEAU HERRIOT | -45,004 | - | - |
| 2026-08-05 | TABUTEAU HERRIOT | -45,004 | $212.01 | $9,541,298 |
| 2026-08-05 | TABUTEAU HERRIOT | +45,004 | $4.95 | $222,770 |
| 2026-07-01 | TABUTEAU HERRIOT | -49,666 | - | - |
| 2026-07-01 | TABUTEAU HERRIOT | -49,666 | $240.25 | $11,932,257 |
| 2026-07-01 | TABUTEAU HERRIOT | +49,666 | $4.95 | $245,847 |
| 2026-06-11 | JEFFS ROGER | -286 | $249.12 | $71,248 |
| 2026-06-10 | JEFFS ROGER | -286 | $246.18 | $70,407 |
| 2026-06-10 | Coleman Mark | -643 | $249 | $160,107 |
| 2026-06-10 | Mahony Susan | -300 | $246.18 | $73,854 |
| 2026-06-09 | Mahony Susan | -300 | $237.21 | $71,163 |
| 2026-06-09 | Pizzie Nick | -33,000 | - | - |
| 2026-06-09 | Pizzie Nick | -33,000 | $240.09 | $7,922,970 |
| 2026-06-09 | Pizzie Nick | +33,000 | $3.5 | $115,500 |
| 2026-06-09 | TABUTEAU HERRIOT | -49,670 | - | - |
| 2026-06-09 | TABUTEAU HERRIOT | -49,670 | $241.01 | $11,970,967 |
| 2026-06-09 | TABUTEAU HERRIOT | +49,670 | $4.95 | $245,867 |
| 2026-06-08 | Coleman Mark | -1,429 | - | - |
| 2026-06-08 | Coleman Mark | +1,429 | - | - |
| 2026-06-08 | Mahony Susan | -1,429 | - | - |
| 2026-06-08 | Mahony Susan | +1,429 | - | - |
| 2026-06-08 | Saad Mark E | -1,429 | - | - |
| 2026-06-08 | Saad Mark E | +1,429 | - | - |
| 2026-06-08 | JEFFS ROGER | -1,429 | - | - |
| 2026-06-08 | JEFFS ROGER | +1,429 | - | - |
| 2026-06-05 | Coleman Mark | +1,721 | - | - |
| 2026-06-05 | Mahony Susan | +1,721 | - | - |
| 2026-06-05 | Saad Mark E | +1,721 | - | - |
| 2026-06-05 | JEFFS ROGER | +1,721 | - | - |
| 2026-06-02 | Coleman Mark | -5,537 | $223.39 | $1,236,910 |
| 2026-06-01 | Coleman Mark | -6,000 | $230.3 | $1,381,800 |
| 2026-05-29 | Coleman Mark | -6,000 | $233.46 | $1,400,760 |
| 2026-05-05 | Jacobson Mark L. | -233 | - | - |
| 2026-05-05 | Jacobson Mark L. | -233 | $228.18 | $53,166 |
| 2026-05-05 | Jacobson Mark L. | +233 | $12.95 | $3,017 |
| 2026-05-04 | Jacobson Mark L. | -4,517 | - | - |
| 2026-05-04 | Jacobson Mark L. | -4,517 | $227.94 | $1,029,605 |
| 2026-05-04 | Jacobson Mark L. | +4,517 | $12.95 | $58,495 |
| 2026-04-22 | Maizel Ari | -7,500 | - | - |
| 2026-04-22 | Maizel Ari | -7,500 | $182.42 | $1,368,150 |
| 2026-04-22 | Maizel Ari | +7,500 | $70.73 | $530,475 |
| 2026-04-21 | Jacobson Mark L. | +8,669 | - | - |
| 2026-04-21 | Maizel Ari | +7,224 | - | - |
| 2026-04-21 | Pizzie Nick | +8,188 | - | - |
| 2026-04-21 | Murdock Hunter R. | +7,224 | - | - |
| 2026-04-21 | TABUTEAU HERRIOT | +24,081 | - | - |
| 2026-02-26 | Pizzie Nick | +18,570 | - | - |
| 2026-02-26 | Murdock Hunter R. | +16,385 | - | - |
| 2026-02-26 | Maizel Ari | +16,385 | - | - |
| 2026-02-26 | Jacobson Mark L. | +19,663 | - | - |
| 2026-02-26 | Coleman Mark | -25,000 | $161.11 | $4,027,750 |
| 2026-02-26 | Jacobson Mark L. | -35,378 | - | - |
| 2026-02-26 | Jacobson Mark L. | -35,378 | $161.88 | $5,726,991 |
| 2026-02-26 | Jacobson Mark L. | +35,378 | $2.85 | $100,827 |
| 2026-02-26 | TABUTEAU HERRIOT | +54,623 | - | - |
| 2026-02-23 | Coleman Mark | -6,250 | - | - |
| 2026-02-23 | Coleman Mark | +6,250 | $4.95 | $30,938 |
| 2026-02-20 | Coleman Mark | -12,485 | - | - |
| 2026-02-20 | Coleman Mark | +12,485 | $4.95 | $61,801 |
| 2026-02-10 | Coleman Mark | -5,193 | - | - |
| 2026-02-10 | Coleman Mark | +5,193 | $8.02 | $41,648 |
| 2026-02-02 | TABUTEAU HERRIOT | -32,410 | - | - |
| 2026-02-02 | TABUTEAU HERRIOT | -32,410 | $185.6 | $6,015,296 |
| 2026-02-02 | TABUTEAU HERRIOT | +32,410 | $8.02 | $259,928 |
| 2026-01-22 | Pizzie Nick | -12,000 | - | - |
| 2026-01-22 | Pizzie Nick | -12,000 | $187.92 | $2,255,040 |
| 2026-01-22 | Pizzie Nick | +12,000 | $3.5 | $42,000 |
| 2026-01-21 | Maizel Ari | -7,500 | - | - |
| 2026-01-21 | Maizel Ari | -7,500 | $184.44 | $1,383,300 |
| 2026-01-21 | Maizel Ari | +7,500 | $70.73 | $530,475 |
| 2026-01-07 | TABUTEAU HERRIOT | -31,261 | - | - |
| 2026-01-07 | TABUTEAU HERRIOT | -31,261 | $170.38 | $5,326,249 |
| 2026-01-07 | TABUTEAU HERRIOT | +31,261 | $8.02 | $250,713 |
| 2026-01-06 | TABUTEAU HERRIOT | -29,450 | - | - |
| 2026-01-06 | TABUTEAU HERRIOT | -29,450 | $172.33 | $5,075,119 |
| 2026-01-06 | TABUTEAU HERRIOT | +29,450 | $8.02 | $236,189 |
| 2026-01-05 | TABUTEAU HERRIOT | -78,703 | - | - |
| 2026-01-05 | TABUTEAU HERRIOT | -78,703 | $171.28 | $13,480,250 |
| 2026-01-05 | TABUTEAU HERRIOT | +78,703 | $8.02 | $631,198 |
| 2025-12-31 | Saad Mark E | -31,346 | - | - |
| 2025-12-31 | Saad Mark E | -6,231 | - | - |
| 2025-12-31 | Saad Mark E | -31,346 | $165.18 | $5,177,732 |
| 2025-12-31 | Saad Mark E | +31,346 | $4.95 | $155,163 |
| 2025-12-31 | Saad Mark E | -6,231 | $165.18 | $1,029,237 |
| 2025-12-31 | Saad Mark E | +6,231 | $8.02 | $49,973 |
| 2025-12-04 | TABUTEAU HERRIOT | -10,558 | - | - |
| 2025-12-04 | TABUTEAU HERRIOT | -10,558 | $148.18 | $1,564,484 |
| 2025-12-04 | TABUTEAU HERRIOT | +10,558 | $8.02 | $84,675 |
| 2025-12-03 | TABUTEAU HERRIOT | -20,163 | - | - |
| 2025-12-03 | TABUTEAU HERRIOT | -20,163 | $146.94 | $2,962,751 |
| 2025-12-03 | TABUTEAU HERRIOT | +20,163 | $8.02 | $161,707 |
| 2025-12-02 | TABUTEAU HERRIOT | -49,252 | - | - |
| 2025-12-02 | TABUTEAU HERRIOT | -49,252 | $144.59 | $7,121,347 |
| 2025-12-02 | TABUTEAU HERRIOT | +49,252 | $8.02 | $395,001 |
| 2025-11-05 | TABUTEAU HERRIOT | -21,775 | - | - |
| 2025-11-05 | TABUTEAU HERRIOT | -21,775 | $134.49 | $2,928,520 |
| 2025-11-05 | TABUTEAU HERRIOT | +21,775 | $8.02 | $174,636 |
| 2025-11-04 | TABUTEAU HERRIOT | -50,459 | - | - |
| 2025-11-04 | TABUTEAU HERRIOT | -50,459 | $133.79 | $6,750,910 |
| 2025-11-04 | TABUTEAU HERRIOT | +50,459 | $8.02 | $404,681 |
| 2025-11-03 | TABUTEAU HERRIOT | -91,705 | - | - |
| 2025-11-03 | TABUTEAU HERRIOT | -91,705 | $132.34 | $12,136,240 |
| 2025-11-03 | TABUTEAU HERRIOT | +91,705 | $8.02 | $735,474 |
| 2025-10-08 | TABUTEAU HERRIOT | -12,774 | - | - |
| 2025-10-08 | TABUTEAU HERRIOT | -12,774 | $118.84 | $1,518,062 |
| 2025-10-08 | TABUTEAU HERRIOT | +12,774 | $8.02 | $102,447 |
| 2025-10-07 | TABUTEAU HERRIOT | -13,390 | - | - |
| 2025-10-07 | TABUTEAU HERRIOT | -13,390 | $118.77 | $1,590,330 |
| 2025-10-07 | TABUTEAU HERRIOT | +13,390 | $8.02 | $107,388 |
| 2025-10-06 | TABUTEAU HERRIOT | -19,220 | - | - |
| 2025-10-06 | TABUTEAU HERRIOT | -19,220 | $120.17 | $2,309,667 |
| 2025-10-06 | TABUTEAU HERRIOT | +19,220 | $8.02 | $154,144 |